Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis. - Wikidata - wikimedia - TriplyDB

Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis.

Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis.

http://www.wikidata.org/entity/Q37856911

about

Bisphosphonate drug holiday: choosing appropriate candidates Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays.Bisphosphonate treatment and risk of esophageal cancer: a meta-analysis of observational studies.Clinical utility of denosumab for treatment of bone loss in men and women Risk of atrial fibrillation among bisphosphonate users: a multicenter, population-based, Italian study.Heart failure as a risk factor for osteoporosis and fractures.Long-term risks of bisphosphonate therapy.Ginsenoside Re Promotes Osteoblast Differentiation in Mouse Osteoblast Precursor MC3T3-E1 Cells and a Zebrafish Model.Les bisphosphonates dans le traitement de l’ostéoporose: Bienfaits attendus, torts potentiels et congés thérapeutiques.

P2860

Q27004682-6E9DE01E-D817-4D96-9428-B8A4C70BA6EE Q33715141-AB08B6A3-2524-4AF1-B817-113C2610D889 Q34305113-34403561-8FA7-4E9A-90EE-4DF113B446D0 Q35092799-DAE51665-D6A2-43C9-AF24-D2F72C16E3E3 Q35597843-FA133E28-66D2-404A-87C1-AF14D41DF168 Q38036949-2DA26E93-5366-4776-975C-0410805307D6 Q38244171-AE8E5806-0D89-4C03-806D-389446EDE14F Q38723595-36D83A24-AD48-4DE4-91FC-AA3FA8AED18E Q55452474-CE87BA26-7467-44C0-A356-33F1A9CB1234

P2860

Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis.

http://www.wikidata.org/entity/Q37856911

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 24 March 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis.

@en

Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis.

@nl

type

label

Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis.

@en

Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis.

@nl

prefLabel

Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis.

@en

Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis.

@nl

P1433

Q37856911-2533E3F0-9909-47F2-81DF-7D3F3EBD89BB

P1476

Q37856911-ED7802CD-2D70-4140-AFDB-E65B552670A3

P2093

Q37856911-07148513-37B5-493C-A3B5-A4B479DC349A

Q37856911-495A6490-F78B-4AAF-9A52-239B22950ED1

Q37856911-535AA2F2-4060-4AF3-AB7C-AF508CA3CAC8

P2860

Q37856911-0CD6B8E2-74C2-4AE2-B996-4D74B2F649F4

Q37856911-10DDD5FF-07DB-4E72-A9F2-CB40B34A2CFB

Q37856911-13B80A93-7FB4-4EE4-BC95-1BD12CFC3A99

Q37856911-16B74CDE-C352-412F-96EB-C4F89D8865BD

Q37856911-1C5563DB-9BB2-4CE0-A458-FA98201D885E

Q37856911-3300BD3C-709E-4C3C-8B07-495C505E3683

Q37856911-382F9BB2-4487-4B57-9CA7-E1BFB4F9FA65

Q37856911-44AE8BFD-BDC3-4E13-9AF1-68FB45E4BD5B

Q37856911-4BE2A857-2C41-4D9B-AB2D-FE6060591E8B

Q37856911-5A955779-83D3-4326-B51A-C33638652888

P2888

Q37856911-646BFBC0-7686-4FAB-A17B-8CB49F5D619E

P304

Q37856911-1523235B-D699-4711-8FED-3DD7E2240DF4

P31

Q37856911-7527FE6C-F0FA-40EA-A1B1-C67BD19BBE55

P356

Q37856911-4C7DEB06-F7B9-4223-A7F9-3118A80F894B

P407

Q37856911-200664D9-FCA4-491C-8A35-9B43AC36538D

P433

Q37856911-735C7898-FFA9-4190-98DD-78D225B68EB7

P478

Q37856911-B7531B1F-97AB-4CE9-B052-FA9F5B371EFE

P50

Q37856911-423D03E9-CE04-4069-814B-83BF00BEC15B

Q37856911-56E95D00-ADA3-48F3-8824-D9B336F1863E

P577

Q37856911-1BBD07C0-364B-40A6-8D3A-B70B9C30CEB2

P5875

Q37856911-4F88F2FB-6B9C-41BE-9812-02275644C69B

P698

Q37856911-EEA65544-AB93-474E-987D-40386CEA3B9E

P921

Q37856911-733A4714-B455-4679-AA61-D887170FCD73

Q37856911-9BE4A5C2-6B21-4F8A-BEDF-6BB50061EC6C

P356

S00198-011-1608-Z

P1433

Osteoporosis International

P1476

Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis

@en

P2093

B J Park

http://www.w3.org/2001/XMLSchema#string

C W Rhee

http://www.w3.org/2001/XMLSchema#string

J Lee

http://www.w3.org/2001/XMLSchema#string

P2860

The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins

Prevalence of and risk factors for atrial fibrillation in Korean adults older than 40 years.

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

Bisphosphonates: an overview with special reference to alendronate.

Lifetime risk for development of atrial fibrillation: the Framingham Heart Study.

Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study.

Use of alendronate and risk of incident atrial fibrillation in women.

Bone safety of long-term bisphosphonate treatment.

Aortic atherosclerotic disease and stroke.

P2888

s00198-011-1608-z

P304

247-254

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00198-011-1608-Z

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-03-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225501833

http://www.w3.org/2001/XMLSchema#string

P698

21431993

http://www.w3.org/2001/XMLSchema#string

P921

atrial fibrillation